Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linerixibat for cholestatic pruritus in primary biliary cholangitis
CTR20212220Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Linerixibat with Placebo (2 arms). Primary endpoint: Change from baseline in monthly pruritus score (0–10 NRS) over 24 weeks. Started Sep 2021; status: completed.
02
Drugs
linerixibat
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on CTR20212220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212220.